Literature DB >> 3154310

Verapamil and diet halt progression of atherosclerosis in cholesterol fed rabbits.

R E Sievers1, T Rashid, J Garrett, S Blumlein, W W Parmley.   

Abstract

The present study was designed to evaluate the effects of oral verapamil and normal diet on regression of atherosclerotic plaque in cholesterol fed rabbits. Forty-three rabbits were separated into 6 groups and studied for 24 weeks. All groups had a cholesterol diet for the first 12 weeks. Group I was then sacrificed and had 38 +/- 23% (mean +/- standard deviation) aortic plaque. During weeks 13 to 24, group II (cholesterol diet) and group III (normal diet) had similar percentages of aortic plaque: 80 +/- 7% and 78 +/- 22%, respectively. Group IV (cholesterol diet), was treated with oral verapamil for 24 weeks and had significantly less plaque (54 +/- 10%) than group II, (80 +/- 7%). In group V (cholesterol diet), treatment with oral verapamil during weeks 13 to 24 did not significantly reduce plaque (70 +/- 23%), compared to group II, (80 +/- 7%). In group VI, normal diet and verapamil during weeks 13 to 24 significantly reduced aortic plaque (46 +/- 25) when compared to group II (80 +/- 7%). Group VI (46%) did not differ from group I (38%). It is concluded that verapamil combined with a normalized diet can halt the progression of aortic atherosclerosis after a 12 week atherogenic diet in rabbits. Verapamil or diet alone was ineffective in the second 12 weeks. Overall, verapamil was effective in preventing atherosclerosis but was ineffective in causing regression of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3154310     DOI: 10.1007/bf02125835

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  24 in total

1.  OBSERVATIONS CONCERNING THE EVOLUTION OF ATHEROSCLEROSIS IN THE RABBIT AFTER CESSATION OF CHOLESTEROL FEEDING.

Authors:  M FRIEDMAN; S O BYERS
Journal:  Am J Pathol       Date:  1963-09       Impact factor: 4.307

2.  Production of advanced cholesterol atherosclerosis in the rabbit.

Authors:  P CONSTANTINIDES; J BOOTH; G CARLSON
Journal:  Arch Pathol       Date:  1960-12

3.  The effects of propranolol on cholesterol-induced atheromatous lesions.

Authors:  P J Whittington-Coleman; O Carrier; B H Douglas
Journal:  Atherosclerosis       Date:  1973 Sep-Oct       Impact factor: 5.162

4.  Effects of agents altering vascular calcium in experimental atherosclerosis.

Authors:  P J Whittington-Coleman; O Carrier
Journal:  Atherosclerosis       Date:  1970 Jul-Aug       Impact factor: 5.162

5.  Experimental atherosclerosis in rabbits with special reference to reversal.

Authors:  P P Gupta; H D Tandon; V Ramalingaswami
Journal:  J Pathol       Date:  1970-08       Impact factor: 7.996

Review 6.  Modification of experimental atherosclerosis by calcium-channel blockers.

Authors:  W W Parmley; S Blumlein; R Sievers
Journal:  Am J Cardiol       Date:  1985-01-25       Impact factor: 2.778

7.  Suppression of calcific fibrous-fatty plaque formation in rabbits by agents not affecting elevated serum cholesterol levels. The effect of thiophene compounds.

Authors:  C T Chan; H Wells; D M Kramsch
Journal:  Circ Res       Date:  1978-07       Impact factor: 17.367

8.  Suppression of experimental atherosclerosis by the Ca++-antagonist lanthanum. Possible role of calcium in atherogenesis.

Authors:  D M Kramsch; A J Aspen; C S Apstein
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

9.  Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbit arterial smooth muscle cells. A possible mechanism for its antiatherogenic effect.

Authors:  O R Etingin; D P Hajjar
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

10.  Verapamil suppresses atherosclerosis in cholesterol-fed rabbits.

Authors:  J L Rouleau; W W Parmley; J Stevens; J Wikman-Coffelt; R Sievers; R W Mahley; R J Havel
Journal:  J Am Coll Cardiol       Date:  1983-06       Impact factor: 24.094

View more
  10 in total

1.  Quantitative analysis of antiatherosclerotic effect of nifedipine in cholesterol-fed rabbits.

Authors:  Y Ohta; N Higuchi; S Emura; T Takashima; K Oogushi; H Kato; K Ohmori; T Sunaga
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy).

Authors:  P R Lichtlen; P G Hugenholtz; W Rafflenbeul; H Hecker; S Jost; P Nikutta; J W Deckers
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals.

Authors:  C Napoli; M Chiariello; G Palumbo; G Ambrosio
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

Review 4.  Calcium antagonists--future uses.

Authors:  R Krebs
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

5.  Effect of verapamil on intimal thickening and vascular reactivity in the collared carotid artery of the rabbit.

Authors:  L Ustünes; M Yasa; Z Kerry; N Ozdemir; T Berkan; Y Erhan; A Ozer
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 6.  Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

Review 7.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

Review 8.  Can the coronary atherosclerotic process be influenced by calcium antagonists?

Authors:  G Kober; W Schneider; G Cieslinski; M Kaltenbach
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 9.  Effect of verapamil on atherosclerosis.

Authors:  G Leonetti; L Sampieri; R Bragato; G Comerio
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 10.  Concept of an antiatherosclerotic efficacy of calcium entry blockers. INTACT Investigators.

Authors:  S Jost; W Rafflenbeul; J Deckers; B Wiese; H Hecker; P Nikutta; P Lippolt; P Lichtlen
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.